GSK plc

GSK

GSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical company headquartered in London, England.

About GSK plc

Latest GSK plc Share price

LON: GSK Dividends

Historical Data

Latest GSK plc News

GSK

GSK receives EU approval for Nucala in Eosinophilic COPD

GSK plc announced that the European Commission has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with uncontrolled...
GSK

GSK reports strong 2025 results and reaffirms long-term growth outlook

GSK delivered a strong financial performance in 2025, with sales of ÂŁ32.7 billion driven by double-digit growth in Specialty Medicines...
GSK

EU approves GSK’s Arexvy RSV vaccine for adults 18+

GSK plc announced that the European Commission has approved its RSV vaccine, Arexvy, for use in adults aged 18 years...
GSK Shingrex

GSK’s Shingrix Prefilled Syringe Approved in Europe

GSK has received European Commission approval for a prefilled syringe presentation of its Shingrix shingles vaccine....
GSK

GSK Plc receives China approval for Nucala in COPD treatment

GSK plc has announced that China’s National Medical Products Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for...
GSK Plc

GSK Plc reaches US agreement to reduce prescription medicine costs

GSK has entered into an agreement with the US Administration to lower the cost of prescription medicines for American patients,...
GSK

GSK secures FDA approval for Exdensur in severe eosinophilic asthma

GSK plc has received US FDA approval for Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma with an...
GSK plc

GSK Plc secures UK approval for Exdensur in asthma and nasal polyps

GSK has announced that Exdensur (depemokimab) has received marketing authorisation from the UK MHRA for use in certain asthma and...
GSK plc

GSK RSV vaccine recommended for wider adult use, CHMP backs expansion

GSK has announced that the EMA’s CHMP has recommended broadening the indication of its adjuvanted RSV vaccine to adults aged...
GSK

GSK receives US FDA Orphan Drug Designation for SCLC treatment risvutatug rezetecan

GSK has announced that its B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, has been granted Orphan Drug Designation by the US FDA...
GSK

GSK subsidiary TESARO starts legal action over Jemperli licence dispute

TESARO, part of GSK, has filed a case in the Delaware Chancery Court claiming AnaptysBio has breached its licence agreement...
GSK Plc

GSK Plc lifts 2025 guidance after strong Q3 sales and profit growth

GSK reported Q3 2025 sales of ÂŁ8.5 billion, up 8% at constant exchange rates, driven by strong performances across Specialty...

Share this page

Twitter
LinkedIn
Facebook
Email
WhatsApp

Data policy – All information should be used for indicative purposes only. You should independently check data before making any investment decision and or seek professional advice. DirectorsTalk cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used.